Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05001880 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
A Phase 2 study of Peritoneal Malignant Mesothelioma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 20
- Study locations
NCT05001880: Recruiting Phase 2 study of Peritoneal Malignant Mesothelioma, sponsored by National Cancer Institute (NCI).
NCT05001880 is a Phase 2 study of Peritoneal Malignant Mesothelioma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 66 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05001880, a Phase 2 study of Peritoneal Malignant Mesothelioma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
Primary Outcome
Will be compared between arms.
Conditions Studied
Interventions
- DRUG Carboplatin
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- BIOLOGICAL Atezolizumab
- BIOLOGICAL Bevacizumab
Study Locations (20)
Minnesota
- Sanford Joe Lueken Cancer Center - Bemidji
- Mercy Hospital - Coon Rapids
- Fairview Southdale Hospital - Edina
- Unity Hospital - Fridley
- Abbott-Northwestern Hospital - Minneapolis
- Mayo Clinic in Rochester - Rochester
- Park Nicollet Clinic - Saint Louis Park - Saint Louis Park
- Regions Hospital - Saint Paul
- United Hospital - Saint Paul
- Rice Memorial Hospital - Willmar
- Sanford Cancer Center Worthington - Worthington
Illinois
- Alliance for Clinical Trials in Oncology - Chicago
- University of Chicago Comprehensive Cancer Center - Chicago
- Carle at The Riverfront - Danville
- Carle Physician Group-Effingham - Effingham
- Carle Physician Group-Mattoon/Charleston - Mattoon
- Carle Cancer Center - Urbana
- The Carle Foundation Hospital - Urbana
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2026-08-20 |
| Phase | Phase 2 |
What NCT05001880 shows while recruiting
NCT05001880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Peritoneal Malignant Mesothelioma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05001880 names 20 study sites across 4 states, led by Minnesota, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT05001880 about?
NCT05001880 is a clinical study titled "Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma". This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of me...
What is the current status of trial NCT05001880?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2022-03-22. Estimated completion is 2026-08-20.
What conditions does trial NCT05001880 study?
This clinical trial studies the following conditions: Peritoneal Malignant Mesothelioma.
What interventions are being tested in trial NCT05001880?
The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Atezolizumab (BIOLOGICAL), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05001880?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05001880 being conducted?
This trial has 20 study locations across Arizona, Illinois, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peritoneal Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05001880's enrollment target sits among peer trials
66 975th of 2000 higher than 1,015 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI